MedTrace Logo

Thrombogenicity Assessment in Patients Treated With Bioresorbable Vascular Scaffolds

NCT03033862 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2020-06-16

No results posted yet for this study

Summary

Platelet activation and aggregation, intrinsic thrombogenicity, and biomarkers (fibrinogen, C-reactive protein, platelet endothelial cell adhesion molecule, von Willebrand factor, p-selectin) will be measured and compared following the implantation of Bioreabsorbable Vascular Scaffolds and Drug Eluting Stents.

Conditions

Interventions

DEVICE

Bioresorbable Vascular Scaffold

Bioresorbable Vascular Scaffold

DEVICE

Drug Eluting Stent

Drug Eluting Stent

Sponsors & Collaborators

  • Inova Health Care Services

    lead OTHER

Principal Investigators

  • Paul A Gurbel, MD · Inova Health Care Services

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-01
Primary Completion
2017-07-01
Completion
2017-07-01
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03033862 on ClinicalTrials.gov